RxDoctor Payments Data

Karen Caruso

Family · San Juan Capistrano, CANPI 1679816680

Payments from drug & device makers

$1,059in general payments, 2019–2025

Across 25 payments — averaging $42.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$207
  • Abbott$174
  • Amgen$158
  • Novo Nordisk$112
  • Inspire Medical Systems, Inc.$106
  • CMP Pharma, Inc.$66
  • plus $236 from 7 others

What the payments were for

  • Food & beverage$1,059100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,059 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$61,986
Medicare patients
405
Services billed
623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine24$87,404
IngrezzaValbenazine Tosylate24$86,707
EliquisApixaban52$28,714
XifaxanRifaximin17$26,960
GemtesaVibegron77$18,488
NorliqvaAmlodipine Besylate21$13,827
JardianceEmpagliflozin20$13,312
XareltoRivaroxaban37$10,501
Breo ElliptaFluticasone/Vilanterol11$4,843
FarxigaDapagliflozin Propanediol13$3,770
Memantine Hcl93$2,092
Memantine Hcl ErMemantine Hcl29$2,080
PradaxaDabigatran Etexilate Mesylate16$1,655
Atorvastatin Calcium193$1,652
Levetiracetam52$1,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$207$86,70724 claims
PfizerEliquis$37$28,71452 claims
Sumitomo Pharma America, Inc.Gemtesa$24$18,48877 claims
CMP Pharma, Inc.Norliqva$66$13,82721 claims
Lilly USA, LLCHumalog$26$47211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in San Juan Capistrano

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →